Overview
Delta Sleep-Inducing Peptide (DSIP) is a 9-amino-acid peptide first isolated in 1977 by the Schoenenberger / Monnier group from rabbit cerebral venous blood collected during electrically induced delta-wave sleep. It generated substantial interest in the 1980s, with a series of small clinical studies in chronic insomnia, narcolepsy, and opioid/alcohol withdrawal — most of them in European labs, most with small sample sizes, and most without independent replication. Interest in DSIP largely faded after the 1990s; the modern peptide-community revival has not been accompanied by new high-quality clinical work. The endogenous receptor for DSIP has never been identified, which is itself a striking gap for a peptide named for a specific physiological function.
Mechanism
Despite the name, DSIP's mechanism of action is not well characterized. No specific receptor has been identified. Proposed mechanisms include modulation of the limbic-hypothalamic axis, possible interaction with opioid systems (relevant to its withdrawal-modulation claims), and pleiotropic neuromodulatory effects. The peptide is reported to cross the blood-brain barrier despite its size, but quantitative CNS pharmacokinetics in humans are essentially absent.
Evidence by indication
We classify each indication separately. The same peptide can be Tier 1 for one use and Tier 4 for another. Tiers reflect the published literature, not the strength of community framing.
Chronic insomnia / sleep quality
Several small open-label and pseudo-controlled studies in the 1980s reported subjective sleep improvements in chronic insomnia. Sample sizes were small, methodology was pre-modern, and replication has been minimal. Per Skill Rule 5 (old, unreplicated studies are weaker than they look).
Narcolepsy / disorders of arousal
A few small 1980s reports in narcolepsy and disorders of arousal. Not pursued in the modern sleep-medicine era; has been completely supplanted by orexin antagonists, sodium oxybate, and newer agents.
No primary citations are anchored to this indication — the tier reflects the absence of usable literature, not a missing reference.
Opioid / alcohol withdrawal modulation
Small 1980s European reports of reduced withdrawal severity in opioid-dependent and alcohol-dependent patients. Mechanism plausible (opioid-system interaction). No modern replication; addiction medicine has moved on to better-supported pharmacotherapies.
General 'recovery' / community sleep-stack use
Modern community use (often combined with peptide stacks for 'sleep optimization') is unsupported by any controlled trial in healthy adults. The 1980s clinical work was in patient populations with diagnosed sleep or addiction disorders, not healthy users seeking optimization.
No primary citations are anchored to this indication — the tier reflects the absence of usable literature, not a missing reference.
Studied dose ranges
The ranges below come from published trial protocols where available, and from documented self-experimenter consensus where the literature does not include human dose-finding work. The notes flag which is which.
Community dosing 100–500 mcg SubQ at bedtime is extrapolated from old IV pharmacological work. There is no modern dose-finding study.
Contraindications
- Pregnancy and breastfeeding (no human safety data)
- Concurrent CNS depressants (additive sedation risk has not been characterized in modern trials)
- Active addiction in unmonitored settings (the withdrawal-modulation claim is not robust enough to support unsupervised use)
- Known hypersensitivity to peptide formulations
Reported side effects
- Generally well tolerated in old clinical studies
- Injection-site reactions
- Mild morning drowsiness reported
- Vivid dreams or altered dream recall reported anecdotally
- Long-term human safety data is essentially absent
Reconstitution & storage
Lyophilized powder reconstituted with bacteriostatic water. A 5 mg vial in 2.5 mL BAC water = 2 mg/mL, making a 100 mcg dose = 5 units on a U-100 syringe. Intranasal preparations follow Juno's nasal-spray prep guide.
Storage. Lyophilized: refrigerate. Reconstituted: refrigerate 2–8 °C, use within 30 days.
Open the peptide calculator → to compute exact draw volumes for your specific vial and BAC water choice.
Editorial note
DRAFT — pending Wayne's review. DSIP is a textbook Skill Rule 5 case — a peptide with a captivating discovery story (named for the EEG state it was extracted during), a flurry of 1980s clinical work, and almost no modern follow-up. The peptide's own receptor was never identified. The current community framing as a 'sleep peptide' significantly outpaces the actual data, especially in healthy users. Hold at Tier 3 for studied indications and Tier 4 for the modern wellness-stack use case.
Citations
- [1]Effects of delta sleep-inducing peptide (DSIP) on sleep, mood and endocrine measures in healthy volunteersSchneider-Helmert D, Schoenenberger GA. · Neuropsychobiology · 1986 · PMID 3539635Anchor 1980s clinical study on DSIP and sleep architecture; representative of the era's evidence base.View source
- [2]DSIP in the treatment of withdrawal syndromes from alcohol and opiatesDick P, Costa C, Fayolle K, Grandjean ME, Khoshbeen A, Tissot R. · European Neurology · 1984 · PMID 6499183Anchor 1980s clinical study on DSIP in withdrawal syndromes; supports Tier 3 framing of that indication.View source